{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:29:40Z","timestamp":1793449780739,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,14]]},"DOI":"10.7759\/cureus.94538","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T09:52:44Z","timestamp":1760435564000},"source":"Crossref","is-referenced-by-count":1,"title":["Monotherapy Versus Combination Therapy of Janus Kinase Inhibitors With Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) in Rheumatoid Arthritis: Evidence From a Systematic Review of Randomized Controlled Trials"],"prefix":"10.7759","author":[{"given":"Razaz Galal","family":"Mirghani Idris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliya Awad","family":"Mohammed Nogod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Mohamedalamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima Mohammed","family":"Ahmed Elhaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awadelgeed Widatalla","family":"Yousif Musa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Elzaki","family":"Mohammed Mansoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehab A","family":"Elagab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.31138\/mjr.20230801.oo","article-title":"Overview of rheumatoid arthritis and scientific understanding of the disease","volume":"34","author":"Jahid M","year":"2023","unstructured":"Jahid M, Khan KU, Rehan-Ul-Haq, Ahmed RS. Overview of rheumatoid arthritis and scientific understanding of the disease. Mediterr J Rheumatol. 2023, 34:284-91. 10.31138\/mjr.20230801.oo","journal-title":"Mediterr J Rheumatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00827-y","article-title":"Global epidemiology of rheumatoid arthritis","volume":"18","author":"Finckh A","year":"2022","unstructured":"Finckh A, Gilbert B, Hodkinson B, et al.. Global epidemiology of rheumatoid arthritis. Nat Rev Rheumatol. 2022, 18:591-602. 10.1038\/s41584-022-00827-y","journal-title":"Nat Rev Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215920","article-title":"Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017","volume":"78","author":"Safiri S","year":"2019","unstructured":"Safiri S, Kolahi AA, Hoy D, et al.. Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis. 2019, 78:1463-71. 10.1136\/annrheumdis-2019-215920","journal-title":"Ann Rheum Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.5114\/reum.2020.101400","article-title":"Conventional disease-modifying agents in rheumatoid arthritis - a review of their current use and role in treatment algorithms","volume":"58","author":"Padjen I","year":"2020","unstructured":"Padjen I, Crnogaj MR, Ani\u0107 B. Conventional disease-modifying agents in rheumatoid arthritis - a review of their current use and role in treatment algorithms. Reumatologia. 2020, 58:390-400. 10.5114\/reum.2020.101400","journal-title":"Reumatologia"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.32598\/IMMUNOREGULATION.6.2.4","article-title":"Reviewing advances in rheumatoid arthritis treatment: from disease-modifying antirheumatic drugs to innovative drug delivery systems","volume":"6","author":"Ghazanfari MR","year":"2024","unstructured":"Ghazanfari MR, Sepehrnia S. Reviewing advances in rheumatoid arthritis treatment: from disease-modifying antirheumatic drugs to innovative drug delivery systems. Immunoregulation. 2024, 6:105-18. 10.32598\/IMMUNOREGULATION.6.2.4","journal-title":"Immunoregulation"},{"key":"ref6","article-title":"Conventional disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis","author":"Hill S","year":"2021","unstructured":"Hill S, Frey N. Conventional disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis. Canadian Journal of Health Technologies. 2021,","journal-title":"Canadian Journal of Health Technologies"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.5RU0519-145R","article-title":"JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy","volume":"106","author":"Gremese E","year":"2019","unstructured":"Gremese E, Alivernini S, Tolusso B, Zeidler MP, Ferraccioli G. JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy. J Leukoc Biol. 2019, 106:1063-8. 10.1002\/JLB.5RU0519-145R","journal-title":"J Leukoc Biol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0757-2","article-title":"Efficacy of monotherapy with biologics and JAK inhibitors for the treatment of rheumatoid arthritis: a systematic review","volume":"35","author":"Emery P","year":"2018","unstructured":"Emery P, Pope JE, Kruger K, Lippe R, DeMasi R, Lula S, Kola B. Efficacy of monotherapy with biologics and JAK inhibitors for the treatment of rheumatoid arthritis: a systematic review. Adv Ther. 2018, 35:1535-63. 10.1007\/s12325-018-0757-2","journal-title":"Adv Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215163","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)","volume":"78","author":"Tanaka Y","year":"2019","unstructured":"Tanaka Y, Takeuchi T, Tanaka S, et al.. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3). Ann Rheum Dis. 2019, 78:1320-32. 10.1136\/annrheumdis-2019-215163","journal-title":"Ann Rheum Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215164","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan","volume":"78","author":"Takeuchi T","year":"2019","unstructured":"Takeuchi T, Tanaka Y, Tanaka S, et al.. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. Ann Rheum Dis. 2019, 78:1305-19. 10.1136\/annrheumdis-2019-215164","journal-title":"Ann Rheum Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-005051","article-title":"Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomised study","volume":"11","author":"Smolen JS","year":"2025","unstructured":"Smolen JS, Emery P, Rigby W, et al.. Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomised study. RMD Open. 2025, 11:e005051. 10.1136\/rmdopen-2024-005051","journal-title":"RMD Open"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-024-03358-x","article-title":"Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial","volume":"26","author":"van Vollenhoven R","year":"2024","unstructured":"van Vollenhoven R, Strand V, Takeuchi T, et al.. Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial. Arthritis Res Ther. 2024, 26:143. 10.1186\/s13075-024-03358-x","journal-title":"Arthritis Res Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-024-07194-x","article-title":"A prospective randomized-controlled non-blinded comparative study of the JAK inhibitor (baricitinib) with TNF-\u03b1 inhibitors and conventional DMARDs in a sample of Egyptian rheumatoid arthritis patients","volume":"43","author":"Mahmoud EM","year":"2024","unstructured":"Mahmoud EM, Radwan A, Elsayed SA. A prospective randomized-controlled non-blinded comparative study of the JAK inhibitor (baricitinib) with TNF-\u03b1 inhibitors and conventional DMARDs in a sample of Egyptian rheumatoid arthritis patients. Clin Rheumatol. 2024, 43:3657-68. 10.1007\/s10067-024-07194-x","journal-title":"Clin Rheumatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2019.1583711","article-title":"Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: an integrated analysis of Phases 2 and 3 trials","volume":"30","author":"Harigai M","year":"2020","unstructured":"Harigai M, Takeuchi T, Smolen JS, et al.. Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: an integrated analysis of Phases 2 and 3 trials. Mod Rheumatol. 2020, 30:36-43. 10.1080\/14397595.2019.1583711","journal-title":"Mod Rheumatol"},{"key":"ref17","article-title":"Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study","volume":"38","author":"Li Z","year":"2020","unstructured":"Li Z, Hu J, Bao C, et al.. Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study. Clin Exp Rheumatol. 2020, 38:732-41.","journal-title":"Clin Exp Rheumatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/art.41384","article-title":"Efficacy and safety of upadacitinib monotherapy in methotrexate\u2010naive patients with moderately\u2010to\u2010severely active rheumatoid arthritis (SELECT\u2010EARLY): a multicenter, multi\u2010country, randomized, double\u2010blind, active comparator-controlled trial","volume":"72","author":"van Vollenhoven R","year":"2020","unstructured":"van Vollenhoven R, Takeuchi T, Pangan AL, et al.. Efficacy and safety of upadacitinib monotherapy in methotrexate\u2010naive patients with moderately\u2010to\u2010severely active rheumatoid arthritis (SELECT\u2010EARLY): a multicenter, multi\u2010country, randomized, double\u2010blind, active comparator-controlled trial. Arthritis Rheumatol. 2020, 72:1607-20. 10.1002\/art.41384","journal-title":"Arthritis Rheumatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa084","article-title":"Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb\/III study","volume":"59","author":"Kameda H","year":"2020","unstructured":"Kameda H, Takeuchi T, Yamaoka K, et al.. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb\/III study. Rheumatology (Oxford). 2020, 59:3303-13. 10.1093\/rheumatology\/keaa084","journal-title":"Rheumatology (Oxford)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14235","article-title":"Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy","volume":"24","author":"Zeng X","year":"2021","unstructured":"Zeng X, Zhao D, Radominski SC, et al.. Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy. Int J Rheum Dis. 2021, 24:1530-9. 10.1111\/1756-185X.14235","journal-title":"Int J Rheum Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219213","article-title":"Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial","volume":"80","author":"Westhovens R","year":"2021","unstructured":"Westhovens R, Rigby WF, van der Heijde D, et al.. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Ann Rheum Dis. 2021, 80:727-38. 10.1136\/annrheumdis-2020-219213","journal-title":"Ann Rheum Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roac083","article-title":"Long-term safety and efficacy of filgotinib treatment for rheumatoid arthritis in Japanese patients na\u00efve to MTX treatment (FINCH 3)","volume":"33","author":"Atsumi T","year":"2023","unstructured":"Atsumi T, Tanaka Y, Matsubara T, et al.. Long-term safety and efficacy of filgotinib treatment for rheumatoid arthritis in Japanese patients na\u00efve to MTX treatment (FINCH 3). Mod Rheumatol. 2023, 33:657-67. 10.1093\/mr\/roac083","journal-title":"Mod Rheumatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial","volume":"80","author":"Combe B","year":"2021","unstructured":"Combe B, Kivitz A, Tanaka Y, et al.. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Ann Rheum Dis. 2021, 80:848-58. 10.1136\/annrheumdis-2020-219214","journal-title":"Ann Rheum Dis"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial.","volume":"390","author":"Fleischmann R","year":"2017","unstructured":"Fleischmann R, Mysler E, Hall S, et al.. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. . The Lancet. 2017, 390:457-68. 10.1016\/S0140-6736(17)31618-5","journal-title":"The Lancet"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1866-2","article-title":"Safety and efficacy of tofacitinib for up to 9.5\u2009years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study","volume":"21","author":"Wollenhaupt J","year":"2019","unstructured":"Wollenhaupt J, Lee EB, Curtis JR, et al.. Safety and efficacy of tofacitinib for up to 9.5\u2009years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019, 21:89. 10.1186\/s13075-019-1866-2","journal-title":"Arthritis Res Ther"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2857-y","article-title":"Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice","volume":"34","author":"Bykerk VP","year":"2015","unstructured":"Bykerk VP, \u00d6st\u00f6r AJ, Alvaro-Gracia J, et al.. Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice. Clin Rheumatol. 2015, 34:563-71. 10.1007\/s10067-014-2857-y","journal-title":"Clin Rheumatol"},{"key":"ref27","article-title":"Efficacy and safety of tofacitinib in US and non-US rheumatoid arthritis patients: pooled analyses of phase II and III","volume":"34","author":"Cohen SB","year":"2016","unstructured":"Cohen SB, Koenig A, Wang L, Kwok K, Mebus CA, Riese R, Fleischmann R. Efficacy and safety of tofacitinib in US and non-US rheumatoid arthritis patients: pooled analyses of phase II and III. Clin Exp Rheumatol. 2016, 34:32-6.","journal-title":"Clin Exp Rheumatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218510","article-title":"Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme","volume":"80","author":"Cohen SB","year":"2021","unstructured":"Cohen SB, van Vollenhoven RF, Winthrop KL, et al.. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2021, 80:304-11. 10.1136\/annrheumdis-2020-218510","journal-title":"Ann Rheum Dis"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.08.007","article-title":"Risk of malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: a meta-analysis of observational studies","volume":"50","author":"Xie W","year":"2020","unstructured":"Xie W, Yang X, Huang H, Gao D, Ji L, Zhang Z. Risk of malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: a meta-analysis of observational studies. Semin Arthritis Rheum. 2020, 50:930-7. 10.1016\/j.semarthrit.2020.08.007","journal-title":"Semin Arthritis Rheum"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg SR","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al.. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022, 386:316-26. 10.1056\/NEJMoa2109927","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-020-00796-1","article-title":"Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs","volume":"80","author":"Lee YH","year":"2021","unstructured":"Lee YH, Song GG. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs. Z Rheumatol. 2021, 80:379-92. 10.1007\/s00393-020-00796-1","journal-title":"Z Rheumatol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012591","article-title":"Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis","volume":"3","author":"Singh JA","year":"2017","unstructured":"Singh JA, Hossain A, Tanjong Ghogomu E, et al.. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2017, 3:CD012591. 10.1002\/14651858.CD012591","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/422252-monotherapy-versus-combination-therapy-of-janus-kinase-inhibitors-with-conventional-synthetic-disease-modifying-antirheumatic-drugs-csdmards-in-rheumatoid-arthritis-evidence-from-a-systematic-review-of-randomized-controlled-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T09:52:45Z","timestamp":1760435565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/422252-monotherapy-versus-combination-therapy-of-janus-kinase-inhibitors-with-conventional-synthetic-disease-modifying-antirheumatic-drugs-csdmards-in-rheumatoid-arthritis-evidence-from-a-systematic-review-of-randomized-controlled-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":32,"URL":"https:\/\/doi.org\/10.7759\/cureus.94538","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,14]]}}}